Abstract
Notably, 6 of these lncRNAs were associated with modules characterized by the NOD-like receptor signaling pathway and chemokine signaling pathway, suggesting that these lncRNAs may promote the occurrence of IPAH via participating in the pro-inflammatory pathways. In conclusion, our systematic analysis not only improved our understanding of the molecular mechanism, but also provided potential lncRNA biomarkers for further research.
Introduction
Idiopathic pulmonary arterial hypertension (IPAH) is a rare, progressive, and often fatal disease characterized by high blood pressure in the lung arteries, eventually leading to right heart failure. While the physiological outcomes are well-documented, the underlying molecular mechanisms remain partially understood. Current treatments target three main pathways (nitric oxide, endothelin, and prostacyclin), but these are not universally effective. There is a critical need to understand the deeper regulatory layers of the disease—specifically how non-coding regions of the genome, such as long non-coding RNAs (lncRNAs), interact with protein-coding genes (mRNAs) to trigger the inflammation and vascular remodeling observed in IPAH patients.
Methods
The researchers employed a multi-step bioinformatic pipeline to map the IPAH landscape using a publicly available dataset from the Gene Expression Omnibus (GEO, Accession: GSE33463), comprising peripheral blood mononuclear cells (PBMCs) from 30 IPAH cases and 41 healthy donors.
The analysis included:
- Differential Expression Analysis: Identifying genes and lncRNAs with significant expression changes between IPAH patients and healthy controls.
- Functional Enrichment: Utilizing Gene Set Enrichment Analysis (GSEA) to identify active biological pathways (GO & KEGG).
- Network Construction: Building Protein-Protein Interaction (PPI) networks via the STRING database and identifying functional modules using the MCODE plugin in Cytoscape.
- lncRNA-mRNA Integration: Linking specific lncRNAs to functional mRNA modules using Spearman correlation coefficients to identify key regulatory lncRNAs.
Results
Differential Expression and Pathway Analysis
The study identified 3,134 differentially expressed genes (945 up-regulated, 2,189 down-regulated) and 118 differentially expressed lncRNAs (9 up-regulated, 109 down-regulated).
The most significant up-regulated pathways were related to T-cell differentiation and receptor signaling, reinforcing the "inflammation hypothesis" of IPAH. Conversely, metabolism-related pathways accounted for 60% of the top down-regulated KEGG pathways, suggesting significant metabolic reprogramming in the immune cells of IPAH patients.
Network Analysis and lncRNA Regulation
The up-regulated PPI network consisted of 443 nodes and 1,386 edges. Key "hub" genes identified included OAS1, CXCL10, STAT1, and TLR4, with TLR4 showing a connectivity degree greater than 30.
A critical finding was the identification of 7 specific lncRNAs (including LOC643888 and LOC554206) highly correlated with modules involved in the NOD-like receptor and chemokine signaling pathways. Specifically, 6 of these lncRNAs were associated with pro-inflammatory modules. Two lncRNAs, LOC643888 and LOC554206, were directly connected to purinergic receptors (P2RY12, P2RY13, P2RY14) and chemokine receptors (CCR2, CCR5), which are essential for immune cell recruitment.
Discussion
This study identifies a complex regulatory network of mRNAs and lncRNAs driving IPAH. By integrating transcriptomic data with protein-protein interaction networks, the research pinpointed key lncRNAs that appear to orchestrate pro-inflammatory pathways, offering promising new targets for diagnosis and therapy.
However, several limitations remain. This study is primarily computational, and the identified correlations do not prove causation. Experimental validation, such as CRISPR knockouts or RNA interference, is required to confirm these regulatory relationships. Additionally, while PBMCs are a valuable source for biomarkers, they may not perfectly reflect the environment of pulmonary arterial smooth muscle cells. Future research should aim to replicate these networks in lung tissue samples to better understand the primary disease pathology.
Summary updated